secwatch.observer — SEC 8-K summary
======================================

Issuer:     Adaptive Biotechnologies Corp (ADPT)
CIK:        0001478320
Form:       8-K
Filed at:   2022-02-15T23:59:59+00:00
Accession:  0001564590-22-005219
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Adaptive Biotechnologies Q4 revenue +26% to $37.9M; CFO Chad Cohen resigns, interim CFO appointed
--------------------------------------------------------------------------------

- Q4 2021 revenue $37.9M (+26% YoY); net loss $61.4M (vs $44.6M). Full year revenue $154.3M (+57%); net loss $207.3M.
- Sequencing revenue Q4 $23.1M (+81% YoY); clonoSEQ clinical tests Q4 6,356 (+41%), full year 22,516 (+48%).
- Development revenue Q4 $14.9M (-15% YoY); cash, equivalents and marketable securities $570.2M at Dec 31, 2021.
- CFO Chad Cohen resigned effective Feb 15, 2022; Kyle Piskel appointed interim CFO.
- Genentech selected TCR candidate targeting shared cancer neoantigen; T-Detect COVID EUA with over 30,000 tests ordered.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1478320/000156459022005219/0001564590-22-005219-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1478320/000156459022005219/adpt-8k_20220215.htm
  HTML page:      https://secwatch.observer/filing/0001564590-22-005219

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer